Lenalidomida Kern Pharma (Lenalidomide)

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma‑cell and lymphoid proliferation.

• Multiple Myeloma: improves progression‑free survival and overall response when used in combination therapy.
• Myelodysplastic Syndromes with 5q Deletion: reduces transfusion dependence and may improve cytopenias.
• Mantle Cell Lymphoma: contributes to disease control in relapsed or refractory cases.

• Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, leading to selective degradation of transcription factors Ikaros and Aiolos. This results in modulation of the immune microenvironment, inhibition of angiogenesis, and direct anti‑tumor activity against malignant plasma cells and lymphoid cells.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Neutropenia: reduced neutrophil count increasing infection risk.
• Thrombocytopenia: low platelet count leading to easy bruising.
• Anemia: decreased red blood cells causing weakness.
• Diarrhea: loose stools that may require management.
• Rash: skin irritation or erythema.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Severe neutropenia: profound immune suppression with fever.
• Serious infections: opportunistic or bacterial infections.
• Secondary primary malignancies: emergence of new cancers.
• Hepatotoxicity: liver enzyme elevation or injury.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor appropriately.

• Pregnancy: contraindicated (Category X); avoid use in pregnant women and ensure effective contraception.
• Thrombosis risk: assess history and consider prophylactic anticoagulation when indicated.
• Renal impairment: dose adjustment may be required based on creatinine clearance.
• Hepatic impairment: monitor liver function tests regularly.
• Drug interactions: review concomitant medications for potential interactions.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Lenalidomide interacts with several drug classes; careful management is essential.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin): may markedly reduce lenalidomide exposure.
• Anticoagulants (e.g., warfarin): increased risk of bleeding.
• Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide plasma levels.
• P‑gp inhibitors (e.g., verapamil): can raise systemic exposure.
• Immunosuppressants (e.g., cyclosporine): monitor for additive immunosuppression.